Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06556693 · ClinicalTrials.gov registry record · NA

Janus II Feasibility

A NA study of Sleep Apnea, sponsored by Zoll Medical Corporation.

Recruiting
Registry status
NA
Development phase
40
Enrollment target
3
Study locations

NCT06556693 is a NA study of Sleep Apnea that is actively recruiting participants, run by Zoll Medical Corporation. The registered enrollment target is 40 participants, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06556693, a NA study of Sleep Apnea, is actively recruiting participants, sponsored by Zoll Medical Corporation.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target
3
Study locations

Study Summary

The objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.

Conditions Studied

Sleep Apnea

Interventions

  • DEVICE Dual Channel Stimulation

Study Locations (3)

Arizona

  • The Insomnia and Sleep Institute of Arizona LLC - Scottsdale

Michigan

  • The University of Michigan Health-West - Wyoming

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-08-12
Est. Completion 2034-12
Phase NA

Sponsor

Zoll Medical Corporation

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06556693

The ClinicalTrials.gov registry entry for NCT06556693 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,988-participant average among 36 other Sleep Apnea trials with a reported enrollment target (99% lower). The listed sponsor is Zoll Medical Corporation, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sleep Apnea appearing as the primary indexed condition, and to 1 intervention - of which Dual Channel Stimulation is the first listed.

NCT06556693 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Michigan, Ohio.

Frequently Asked Questions

What is clinical trial NCT06556693 about?

NCT06556693 is a clinical study titled "Janus II Feasibility". The objectives of this study are to evaluate the feasibility of the remedē® Dual Channel System at implant and overnight sleep studies and to assess chronic safety.

What is the current status of trial NCT06556693?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2025-08-12. Estimated completion is 2034-12.

What conditions does trial NCT06556693 study?

This clinical trial studies the following conditions: Sleep Apnea.

What interventions are being tested in trial NCT06556693?

The interventions under investigation include: Dual Channel Stimulation (DEVICE).

Who is sponsoring clinical trial NCT06556693?

This trial is sponsored by Zoll Medical Corporation, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06556693 being conducted?

This trial has 3 study locations across Arizona, Michigan, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Sleep Apnea

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Sleep Apnea

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.